Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 16
A Comparative Study on Adipose-Derived Mesenchymal Stem Cells Secretome Delivery Using Microneedling and Fractional CO2 Laser for Facial Skin Rejuvenation [Response to Letter]
Authors Yusharyahya SN , Japranata VV , Sitohang IBS , Legiawati L , Novianto E , Suseno LS , Rachmani K
Received 28 February 2023
Accepted for publication 9 March 2023
Published 15 March 2023 Volume 2023:16 Pages 671—672
Shannaz Nadia Yusharyahya,1 Valdi Ven Japranata,2 Irma Bernadette S Sitohang,1 Lili Legiawati,1 Endi Novianto,1 Lis Surachmiati Suseno,1 Karin Rachmani1
1Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta Pusat, Indonesia; 2Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia
Correspondence: Shannaz Nadia Yusharyahya, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jalan Diponegoro Nomor 71, Kenari, Senen, Jakarta Pusat, 10430, Indonesia, Tel/Fax +62 21 31935383, Email [email protected]
View the original paper by Dr Yusharyahya and colleagues
This is in response to the Letter to the Editor
We thank Ratih Rinendyaputri from National Research and Innovation Agency (BRIN), Indonesia, for the perceptive comments concerning our latest publication entitled “A comparative study on adipose-derived mesenchymal stem cells secretome delivery using microneedling and fractional Co2 laser for facial skin rejuvenation” published in Clinical, Cosmetic and Investigational Dermatology. We solemnly appreciate any valuable input to our work for improvements in the future research, especially regarding stem cell products which have an immense potential in regenerative medicine. Through this article, we would like to address our replies to the concerns raised by the mentioned reader.
First, the reader argued that our clinical trial was established to demonstrate the efficacy and safety of adipose-derived mesenchymal stem cells (ADMSCs) secretome for skin rejuvenation in a dose-dependent manner. While we agree with the importance of secretome dosage for such purpose, as we have explicitly stated in the introduction of our manuscript, the study aims to investigate which administration method (microneedling or fractional CO2) is the best to deliver ADMSCs secretome for alleviating skin aging features.1 Numerous previous studies have reported the effects of stem cell derivatives in the field of dermatology. For instance, a study by Kim et al showed that the conditioned growth medium of ADMSCs incorporated in cosmetic products may exert antiaging properties through collagen synthesis, damaged skin restoration, and dermal density increment.2 Another research by Ahangar et al suggested that a vast repertoire of trophic factors contained in stem cell secretome may support wound repair through paracrine signaling, thus improving re-epithelization, promoting angiogenesis, and controlling inflammation in human skin.3 Damayanti, Rusdiana, and Wathoni also conducted a literature review summarizing the utilization of mesenchymal stem cell secretome in dermatology, eg, protection against photoaging, accelerate hair growth, and treating psoriasis.4 Given the massive prospects of stem cell secretome that have already been discovered, there will be no novelty in performing another clinical trial to explore the efficacy of ADMSCs secretome for the treatment of cutaneous senescence; hence, that is not an interest in our current study.
In addition, the reader emphasized the lack of characterization and protein concentrations of ADMSCs secretome used in our clinical trial. We acknowledge the imperative role of providing detailed delineation of study materials to ensure the replicability of our research. As per written descriptions in our latest paper, we performed quality analysis to our ADMSCs secretome, including the quantitative measurement of its protein contents. However, since our secretome is still prototype and yet to be registered for Intellectual Property Rights to date, we cannot provide the exact concentration of growth factors, interleukins, and other proteins of the final manufactured product. This is also a part of the security measures which is undertaken to keep the manufacturer’s information confidential and to prevent possible conflicts of interests.
In conclusion, the authors greatly value the reader’s contribution to our previous work. We are looking forward to another constructive remarks for the betterment of our prospective projects.
No financial support was received for the publication of this communication letter.
The authors hereby declare that we have no competing conflicts of interests in this communication.
1. Yusharyahya SN, Japranata VV, Sitohang IBS, et al. A comparative study on adipose-derived mesenchymal stem cells secretome delivery using microneedling and fractional CO2 laser for facial skin rejuvenation. Clin Cosmet Investig Dermatol. 2023;16:387–395. doi:10.2147/CCID.S401839
2. Kim K, Kim YS, Lee S, An S. The effect of three-dimensional cultured adipose tissue-derived mesenchymal stem cell–conditioned medium and the antiaging effect of cosmetic products containing the medium. Biomed Dermatol. 2019;4:1. doi:10.1186/s41702-019-0053-z
3. Ahangar P, Mills SJ, Cowin AJ. Mesenchymal stem cell secretome as an emerging cell-free alternative for improving wound repair. Int J Mol Sci. 2020;21(19):7038. doi:10.3390/ijms21197038
4. Damayanti RH, Rusdiana T, Wathoni N. Mesenchymal stem cell secretome for dermatology application: a review. Clin Cosmet Investig Dermatol. 2021;14:1401–1412. doi:10.2147/CCID.S331044
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.